# Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma

## TL;DR

This paper reviews how the tumor immune environment in esophageal cancer varies and how this affects immunotherapy outcomes.

## Contribution

The paper provides a review of the tumor immune microenvironment and immunopredictive models in ESCC, highlighting potential therapeutic strategies.

## Key findings

- The heterogeneity of the tumor immune microenvironment affects immunotherapy outcomes in ESCC.
- Understanding interactions within the tumor immune microenvironment may lead to better treatment strategies.
- Immunopredictive models could help improve immunotherapy efficacy in ESCC patients.

## Abstract

Esophageal cancer is one of the most prevalent malignant tumors of the digestive tract, with esophageal squamous cell carcinoma (ESCC) as its main histological type. In recent years, immunotherapeutic regimens centered on immune checkpoint inhibitors (ICIs) have achieved remarkable efficacy in patients with advanced ESCC. However, due to the heterogeneity of the tumor immune microenvironment (TIME), the degree of clinical benefit varies among patients. This heterogeneity not only affects the biological behavior of tumors but also determines the efficacy and prognosis of immunotherapy. Therefore, exploring the interactions between tumor cells and diverse immunological components inside the TIME in ESCC, as well as how to use ICIs to reshape the TIME, may bring new therapeutic opportunities for ESCC patients. This review looks at the important aspects of TIME and immunological prediction models and explores potential therapeutic strategies targeting both, providing a theoretical basis for improving immunotherapy outcomes in ESCC.